Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit M Wollmann

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 2, 2021
<b>Primary human hepatocyte spheroids as an </b>Julia Riede, Birgit M Wollmann, Espen Molden, et al.
Therapeutic Drug Monitoring|April 13, 2018
Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as BiomarkerKristine Hole, Birgit M Wollmann, Camilla Nguyen, et al.
Therapeutic Drug Monitoring|January 30, 2024
Novel Identification of Cysteinyl Derivatives of Toxic Clozapine Nitrenium Ions and the Effect of Valproic Acid on Metabolite Formation: A Study Using Reprocessed High-Resolution Mass Spectra of Analyzed Therapeutic Drug Monitoring SamplesBirgit M Wollmann, Aina G Haugen, Robert L Smith, et al.
Clinical Pharmacokinetics|June 14, 2021
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring DataTrine Frederiksen, Robert L Smith, Birgit M Wollmann, et al.
Therapeutic Drug Monitoring|December 13, 2018
Substantial Differences in Serum Concentrations of Psychoactive Drugs Measured in Samples Stored for 2 Days or More on Standard Serum Tubes Versus Serum Tubes Containing Gel SeparatorsBirgit M Wollmann, Hilde A Lunde, Lene K Støten, et al.
European Journal of Clinical Pharmacology|February 22, 2023
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotypeBirgit M Wollmann, Elisabet Størset, Marianne Kristiansen Kringen, et al.
Journal of Clinical Psychopharmacology|August 2, 2022
Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment: A Retrospective Pilot StudyLennart Kyllesø, Robert Løvsletten Smith, Birgit M Wollmann, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 12, 2018
Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid ArthritisBirgit M Wollmann, Silje Watterdal Syversen, Maria Vistnes, et al.
British Journal of Clinical Pharmacology|March 24, 2023
Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolismBirgit M Wollmann, Robert L Smith, Marianne Kristiansen Kringen, et al.
British Journal of Clinical Pharmacology|July 31, 2025
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case reportElisabet Størset, Birgit M Wollmann, Sverre Gunnarsson Larne, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 2, 2021
<b>Primary human hepatocyte spheroids as an </b>Julia Riede, Birgit M Wollmann, Espen Molden, et al.
Therapeutic Drug Monitoring|April 13, 2018
Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as BiomarkerKristine Hole, Birgit M Wollmann, Camilla Nguyen, et al.
Therapeutic Drug Monitoring|January 30, 2024
Novel Identification of Cysteinyl Derivatives of Toxic Clozapine Nitrenium Ions and the Effect of Valproic Acid on Metabolite Formation: A Study Using Reprocessed High-Resolution Mass Spectra of Analyzed Therapeutic Drug Monitoring SamplesBirgit M Wollmann, Aina G Haugen, Robert L Smith, et al.
Clinical Pharmacokinetics|June 14, 2021
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring DataTrine Frederiksen, Robert L Smith, Birgit M Wollmann, et al.
Therapeutic Drug Monitoring|December 13, 2018
Substantial Differences in Serum Concentrations of Psychoactive Drugs Measured in Samples Stored for 2 Days or More on Standard Serum Tubes Versus Serum Tubes Containing Gel SeparatorsBirgit M Wollmann, Hilde A Lunde, Lene K Støten, et al.
European Journal of Clinical Pharmacology|February 22, 2023
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotypeBirgit M Wollmann, Elisabet Størset, Marianne Kristiansen Kringen, et al.
Journal of Clinical Psychopharmacology|August 2, 2022
Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment: A Retrospective Pilot StudyLennart Kyllesø, Robert Løvsletten Smith, Birgit M Wollmann, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 12, 2018
Associations between Cytokine Levels and CYP3A4 Phenotype in Patients with Rheumatoid ArthritisBirgit M Wollmann, Silje Watterdal Syversen, Maria Vistnes, et al.
British Journal of Clinical Pharmacology|March 24, 2023
Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolismBirgit M Wollmann, Robert L Smith, Marianne Kristiansen Kringen, et al.
British Journal of Clinical Pharmacology|July 31, 2025
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case reportElisabet Størset, Birgit M Wollmann, Sverre Gunnarsson Larne, et al.
Pageof 2